Continuous treatment with lenalidomide and low‐dose dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial

The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low‐dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant‐ineligible patients with newly diagnosed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Lu, Jin, Lee, Jae H., Huang, Shang‐Yi, Qiu, Lugui, Lee, Je‐Jung, Liu, Ting, Yoon, Sung‐Soo, Kim, Kihyun, Shen, Zhi X., Eom, Hyeon S., Chen, Wen M., Min, Chang K., Kim, Hyo J., Lee, Jeong O., Kwak, Jae Y., Yiu, Wai, Chen, Guang, Ervin‐Haynes, Annette, Hulin, Cyrille, Facon, Thierry
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Haematological Malignancy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5324608/
https://ncbi.nlm.nih.gov/pubmed/28106903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14465
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados